Agne Paner, ASH 2019: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias

Professor Michael Mauro (Memorial Sloan Kettering Cancer Center, New York City, NY, USA) discusses the 48-week update from the ASCEMBL trial, a multicenter, open-label, phase III study of the efficacy and safety of asciminib, a first-in-class STAMP inhibitor, vs Bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: […]

touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) discusses his recent phase II study exploring the benefits, efficacy and safety of tyrosine kinase inhibitors dasatinib–blinatumomab for the treatment of Ph-positive acute lymphoblastic leukemia in adults. Questions What is the rationale for the use of dasatinib plus glucocorticoids, followed by blinatumomab, rather […]

We were delighted to catch up with Dr Pinkal Desai (Weill Cornell Medical College, New York City, NY, USA) to discuss the report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub on clinical predictors of outcome in adult patients with acute leukemias and myelodysplastic syndrome and COVID-19 infection. Questions 1. Prior […]